Expanding use of CD33-directed immunotherapy

References

• Duan S, Paulson JC. Siglecs as immune cell checkpoints in disease. Annu Rev Immunol. 2020;38:365–395.
   PubMed Web of Science ®Google Scholar
• Cowan AJ, Laszlo GS, Estey EH, et al. Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin. Front Biosci (Landmark Ed). 2013;18(4):1311–1334.
   PubMed Web of Science ®Google Scholar
• Walter RB, Appelbaum FR, Estey EH, et al. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood. 2012;119(26):6198–6208.
   PubMed Web of Science ®Google Scholar
• Laszlo GS, Estey EH, Walter RB. The past and future of CD33 as therapeutic target in acute myeloid leukemia. Blood Rev. 2014;28(4):143–153.
   PubMed Web of Science ®Google Scholar
• Godwin CD, Gale RP, Walter RB. Gemtuzumab ozogamicin in acute myeloid leukemia. Leukemia. 2017;31(9):1855–1868.
   PubMed Web of Science ®Google Scholar
• Hills RK, Castaigne S, Appelbaum FR, et al., Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol. 15(9): 986–996. 2014.
   PubMed Web of Science ®Google Scholar
• Walter RB. Investigational CD33-targeted therapeutics for acute myeloid leukemia. Expert Opin Investig Drugs. 2018;27(4):339–348.
   PubMed Web of Science ®Google Scholar
• Godwin CD, Laszlo GS, Wood BL, et al. The CD33 splice isoform lacking exon 2 as therapeutic target in human acute myeloid leukemia. Leukemia. 2020;in press. DOI:10.1038/s41375-020-0755-7.
   Google Scholar
• Nair-Gupta P, Diem M, Reeves D, et al. A novel C2 domain binding CD33xCD3 bispecific antibody with potent T-cell redirection activity against acute myeloid leukemia. Blood Adv. 2020;4(5):906–919.
   PubMed Web of Science ®Google Scholar
• Sallman DA, List A. The central role of inflammatory signaling in the pathogenesis of myelodysplastic syndromes. Blood. 2019;133(10):1039–1048.
   PubMed Web of Science ®Google Scholar
• Jitschin R, Saul D, Braun M, et al. CD33/CD3-bispecific T-cell engaging (BiTE(R)) antibody construct targets monocytic AML myeloid-derived suppressor cells. J Immunother Cancer. 2018;6(1):116.
   PubMedGoogle Scholar
• Eckard S, Gehrs L, Smith V, et al. AMV564, a novel bivalent, bispecific T-cell engager, targets myeloid-derived suppressor cells [abstract]. J Immunother Cancer. 2019;2019(283):229–230.
   Google Scholar
• Gleason MK, Ross JA, Warlick ED, et al. CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood. 2014;123(19):3016–3026.
   PubMed Web of Science ®Google Scholar
• Eksioglu EA, Chen X, Heider KH, et al. Novel therapeutic approach to improve hematopoiesis in low risk MDS by targeting MDSCs with the Fc-engineered CD33 antibody BI 836858. Leukemia. 2017;31(10):2172–2180.
   PubMed Web of Science ®Google Scholar
• Chen X, Eksioglu EA, Zhou J, et al. Induction of myelodysplasia by myeloid-derived suppressor cells. J Clin Invest. 2013;123(11):4595–4611.
   PubMed Web of Science ®Google Scholar
• Garnache-Ottou F, Chaperot L, Biichle S, et al. Expression of the myeloid-associated marker CD33 is not an exclusive factor for leukemic plasmacytoid dendritic cells. Blood. 2005;105(3):1256–1264.
   PubMed Web of Science ®Google Scholar
• Craig FE, Foon KA. Flow cytometric immunophenotyping for hematologic neoplasms. Blood. 2008;111(8):3941–3967.
   PubMed Web of Science ®Google Scholar
• Mateo G, Castellanos M, Rasillo A, et al. Genetic abnormalities and patterns of antigenic expression in multiple myeloma. Clin Cancer Res. 2005;11(10):3661–3667.
   PubMed Web of Science ®Google Scholar
• Ocqueteau M, Orfao A, Almeida J, et al. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. Am J Pathol. 1998;152(6):1655–1665.
   PubMed Web of Science ®Google Scholar
• Almeida J, Orfao A, Ocqueteau M, et al. High-sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma. Br J Haematol. 1999;107(1):121–131.
   PubMed Web of Science ®Google Scholar
• Robillard N, Wuillème S, Lodé L, et al. CD33 is expressed on plasma cells of a significant number of myeloma patients, and may represent a therapeutic target. Leukemia. 2005;19(11):2021–2022.
   PubMed Web of Science ®Google Scholar
• Sahara N, Ohnishi K, Ono T, et al. Clinicopathological and prognostic characteristics of CD33-positive multiple myeloma. Eur J Haematol. 2006;77(1):14–18.
   PubMed Web of Science ®Google Scholar
• Shamsasenjan K, Otsuyama KI, Abroun S, et al. IL-6-induced activation of MYC is responsible for the down-regulation of CD33 expression in CD33+ myeloma cells. Int J Hematol. 2009;89(3):310–318.
   PubMed Web of Science ®Google Scholar
• Robillard N, Wuillème S, Moreau P, et al. Immunophenotype of normal and myelomatous plasma-cell subsets. Front Immunol. 2014;5:137.
   PubMed Web of Science ®Google Scholar
• Shim H, Ha JH, Lee H, et al. Expression of myeloid antigen in neoplastic plasma cells is related to adverse prognosis in patients with multiple myeloma. Biomed Res Int. 2014;2014:893243.
   PubMed Web of Science ®Google Scholar
• Oka S, Ono K, Nohgawa M. Clinical effects of CD33 and MPC-1 on the prognosis of multiple myeloma treated with bortezomib. Leuk Lymphoma. 2019;60(9):2152–2157.
   PubMed Web of Science ®Google Scholar
• Botta C, Gullà A, Correale P, et al. Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities. Front Oncol. 2014;4:348.
   PubMedGoogle Scholar
• Malek E, de Lima M, Letterio JJ, et al. Myeloid-derived suppressor cells: the green light for myeloma immune escape. Blood Rev. 2016;30(5):341–348.
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12(4):253–268.
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI. Myeloid-derived suppressor cells. Cancer Immunol Res. 2017;5(1):3–8.
   PubMed Web of Science ®Google Scholar
• Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age. Nat Immunol. 2018;19(2):108–119.
   PubMed Web of Science ®Google Scholar
• Bizymi N, Bjelica S, Kittang AO, et al. Myeloid-derived suppressor cells in hematologic diseases: promising biomarkers and treatment targets. Hemasphere. 2019;3(1):e168.
   PubMed Web of Science ®Google Scholar
• Epperly R, Gottschalk S, Velasquez MP. A bump in the road: how the hostile AML microenvironment affects CAR T cell therapy. Front Oncol. 2020;10:262.
   PubMed Web of Science ®Google Scholar
• Fleming V, Hu X, Weber R, et al. Targeting myeloid-derived suppressor cells to bypass tumor-induced immunosuppression. Front Immunol. 2018;9:398.
   PubMed Web of Science ®Google Scholar
• Law AMK, Valdes-Mora F, Gallego-Ortega D. Myeloid-derived suppressor cells as a therapeutic target for cancer. Cells. 2020;9(3):E561.
   PubMed Web of Science ®Google Scholar
• Estus S, BC S, Devanney N, et al. Evaluation of CD33 as a genetic risk factor for Alzheimer’s disease. Acta Neuropathol. 2019;138(2):187–199.
   PubMed Web of Science ®Google Scholar
• Miles LA, Hermans SJ, Crespi GAN, et al. Small molecule binding to Alzheimer risk factor CD33 promotes Aβ phagocytosis. iScience. 2019;19:110–118.
   PubMed Web of Science ®Google Scholar
• Godwin CD, McDonald GB, Walter RB. Sinusoidal obstruction syndrome following CD33-targeted therapy in acute myeloid leukemia. Blood. 2017;129(16):2330–2332.
   PubMed Web of Science ®Google Scholar
• Kim MY, Yu KR, Kenderian SS, et al., Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia. Cell. 173(6): 1439–53 e19. 2018.
   PubMed Web of Science ®Google Scholar
• Humbert O, Laszlo GS, Sichel S, et al. Engineering resistance to CD33-targeted immunotherapy in normal hematopoiesis by CRISPR/Cas9-deletion of CD33 exon 2. Leukemia. 2019;33(3):762–808.
   PubMed Web of Science ®Google Scholar
• Borot F, Wang H, Ma Y, et al. Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignancies. Proc Natl Acad Sci U S A. 2019;116(24):11978–11987.
   PubMed Web of Science ®Google Scholar